The Department for Health and Social Care has asked NICE to conduct an appraisal of sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer.
Please note that following on from a request from the company, the timelines for this appraisal have been revised to enable company to facilitate a suitably comprehensive submission.
Therefore, the appraisal is now anticipated to begin during late-April 2021 when we will write to you about how you can get involved.